[Study of antisense oligodeoxynucleotide in reversing multidrug resistance and inducing apoptosis of tumor cells]

Related Experiment Video

Updated: Aug 11, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

F Zhang1, Y Lin, Y Jiang

  • 1The Third Clinical College, Norman Bethune University of Medical Sciences, Changchun 130021.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|January 1, 2005
PubMed
Abstract

Insights

Antisense oligodeoxynucleotide (mdr-1-AS PS-ODN) effectively reverses multidrug resistance in tumor cells by inhibiting mdr-1 gene expression. This approach promotes apoptosis in resistant cancer cells, offering a potential strategy for overcoming treatment challenges.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Context:

  • Multidrug resistance (MDR) in tumor cells poses a significant challenge in cancer chemotherapy.
  • The mdr-1 gene plays a crucial role in the development of MDR.
  • Novel strategies are needed to overcome MDR and improve treatment efficacy.

Purpose:

  • To investigate the potential of antisense oligodeoxynucleotide (mdr-1-AS PS-ODN) in reversing multidrug resistance in tumor cells.
  • To evaluate the effect of mdr-1-AS PS-ODN on mdr-1 gene expression and apoptosis in K562/ADM cells.

Summary:

  • Antisense oligodeoxynucleotide (mdr-1-AS PS-ODN) was utilized to target the mdr-1 gene in multidrug resistant K562/ADM cells.
  • Treatment with mdr-1-AS PS-ODN resulted in the generation of DNA fragments and induced apoptosis in a significant proportion of mdr-1+ K562/ADM cells.
  • The study demonstrated that mdr-1-AS PS-ODN specifically inhibits mdr-1 gene expression.

Impact:

  • mdr-1-AS PS-ODN effectively reverses multidrug resistance in tumor cells.
  • This approach enhances Adriamycin (ADM)-induced apoptosis in mdr-1+ K562/ADM cells.
  • The findings suggest a promising therapeutic strategy for overcoming drug resistance in cancer treatment.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...